Drug Profile

Research programme: food allergy immunotherapeutics - Aimmune Therapeutics/Nestle Health Science

Alternative Names: Food allergy OIT - Aimmune Therapeutics; Food allergy oral immunotherapies - Aimmune Therapeutics

Latest Information Update: 24 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aimmune Therapeutics
Class Allergens; Antiallergics; Food allergy immunotherapies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Food hypersensitivity

Most Recent Events

24 Oct 2024 Discontinued - Preclinical for Food hypersensitivity in USA (PO), before October 2024 (Aimmune Therapeutics pipeline, October 2024)
14 Oct 2020 Aimmune Therapeutics has been acquired by Nestle
28 Oct 2019 No recent reports of development identified for preclinical development in Food-hypersensitivity in USA (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com